EMERGENCY: 1800 330 0000 I CALL: NOIDA : +91-9582833333, GREATER NOIDA : +91-8800447777, NOIDA EXT: +91-8800110086 , JHANSI: +91 8800550084, FARIDABAD: +91-8588833310

BOARD OF DIRECTORS

DR. AJAY KUMAR TYAGI

CHAIRMAN

Ajay Kumar Tyagi is the Chairman and Whole-time Director of our Company. He has been a Director of our Company since its incorporation. He holds a degree of bachelor of medicine and bachelor of surgery from LLRM Medical College, Meerut University. He also holds diploma in orthopaedics from King George Medical College, Lucknow. He has over 16 years of experience in the field of medical care and hospital management. He is responsible for strategic investment and overall guidance for the business of our Company. He was previously associated with Medical Health Family Welfare U.P. L.K.O.

View More

DR. KAPIL KUMAR

MANAGING DIRECTOR

Kapil Kumar is the Managing Director of our Company. He has been a Director of our Company since its incorporation. He holds a degree of bachelor of medicine and bachelor of surgery from SN Medical College, Agra University. Further, he holds a degree of master of surgery in orthopaedic surgery from Lucknow University. He has also completed magister chirurgie in orthopaedics from University of Seychelles, American Institute of Medicine. He has over two decades of experience in field of medicine and health care. He is an orthopaedic surgeon. Further, he is responsible for clinical management of our Company. He was previously associated with Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital and Noida Orthopaedic Hospital as a consultant.

View More

MR. YATHARTH TYAGI

DIRECTOR

Mr. Yatharth Tyagi is Whole-time Director of our Company. He is responsible for overall operations and business development. He has been associated with our Company since 2019. He was appointed as a Director of our Company on September 15, 2021. He holds a bachelor’s degree in business and management from Leeds Beckett University. He also holds a master of science degree in International Health Management from Imperial College London.

Mr. Yatharth has been instrumental in bolstering performance across markets ever since joining the company. He holds the vision to bring about advancements in the field of healthcare and create institutions where patient care is delivered through innovative solutions. His leadership and unconventional strategies not only augmented healthcare capacity but have also fostered an environment of comfort and gratitude within the healthcare setting. He is ensuring the Indian healthcare system becomes robust to cater to the changing landscape of domestic and international health concerns.

View More

INDEPENDENT DIRECTORS

MS. PROMILA BHARDWAJ

INDEPENDENT DIRECTOR

Ms. Promila Bhardwaj is an Independent Director of our Company. She has been a Director of our Company since October 22, 2022. She holds a degree in Bachelor’s of Arts, Master’s of Arts in English and Master’s of Philosophy from Punjab University. She also holds a Master’s Diploma in Public Administration from Indian Institute of Public Administration. She Joined Indian Revenue Services (“IRS”) in 1979 and served various positions like Deputy Secretary under Ministry of Water Resources, Director of Industrial Policy and Promotion, Personal Secretary to Minister of State for Women and Child Development, Director General (HRD) (International Taxation & Transfer Pricing) & (Systems) and Chief Commissioner of Income Tax. Currently she is Independent Director in two listed companies and other public companies. She is also being member of various committees like Audit Committee, Nomination and Remuneration Committee, CSR Committee etc

View More

MR. MUKESH SHARMA

INDEPENDENT DIRECTOR

Mukesh Sharma is an Independent Director of our Company. He has been a Director of our Company since February 21, 2022. He holds a bachelor’s degree in science agriculture and animal husbandry from Govind Ballabh Pant University of Agriculture and Technology. He also holds a master’s degree in business administration and has completed post graduate diploma in labour law, labour welfare and personnel management from Maharshi Dayanand Saraswati University, Ajmer. Further, he holds a degree of bachelor’s of law from Chaudhary Charan Singh University, Meerut. He has over 35 years of experience in banking and was previously associated with Bank of Baroda. Currently, he is a SARFAESI Internal Ombudsman at Bank of Baroda

View More

DR. SANJEEV UPADHYAYA

INDEPENDENT DIRECTOR

Dr. Sanjeev Upadhyaya is an Independent Director of our Company. He has been a Director of our Company since February 21, 2022. He holds a bachelor’s degree in medicine and bachelor of surgery from Meerut University. He also holds a degree of doctor of medicine in community medicine from Nagpur University. He has over 20 years of experience in community medicines. He was previously associated with E.S.I. Hospital as house surgeon and Aga Khan Foundation Project as public health specialist. He was also associated with University College of Medical Sciences &Guruteg Bahadur Hospital; and Lady Hardinge Medical College & Associated Hospital as senior resident. Further, he was also associated with United States Agency for International Development, India as project management specialist (in Population, Health and Nutrition Office/ Maternal, Child Health Nutrition & Urban Health Division). He was an experienced Health Specialist at the United Nations Children's Fund

View More

COMPOSITION OF COMMITTEE

Sr. No. Committee Name of Director Role in Committee Category of Director
1 Audit Committee Mr.Mukesh Sharma Member & Chairman Independent Director
Ms. Promila Bhardwaj Member Independent Director
Dr. Ajay Kumar Tyagi Member Chairman
2 Nomination and Remuneration Committee Dr. Sanjeev Upadhyaya Member & Chairman Independent Director
Mr.Mukesh Sharma Member Independent Director
Ms. Promila Bhardwaj Member Independent Director
3 Stakeholders Relationship Committee Ms. Promila Bhardwaj Member & Chairman Independent Director
Dr. Ajay Kumar Tyagi Member Chairman
Dr. Kapil Kumar Member Managing Director
4 CSR Committee Dr. Ajay Kumar Tyagi Member & Chairman Chairman
Dr. Kapil Kumar Member Managing Director
Dr. Sanjeev Upadhyaya Member Independent Director
5 Risk Management Committee Dr. Ajay Kumar Tyagi Member & Chairman Chairman
Mr. Mukesh Sharma Member Independent Director
Dr. Kapil Kumar Member Managing Director
6 Banking and Finance Committee Dr. Ajay Kumar Tyagi Member & Chairman Managing Director
Dr. Kapil Kumar Member Managing Director
Mr. Yatharth Tyagi Member Whole-Time Director

KEY MANAGEMENT PERSONNEL

MR. AMIT SINGH

GROUP C.E.O

Mr Amit Singh is a healthcare management professional with 16 years of experience in providing operations leadership, strategic planning, quality & business development with various healthcare organizations. He has been a part of the management of various premiere healthcare institutions. Prior to joining Yatharth group he has served as vice president at BLK Hospital, Delhi, group vice president at Centre for Sight group, chief operating officer at Point Hospitals and business head at Raksha Medicare. He has extensive experience of setting up a chain of hospitals. He has proven experience in field of strategic planning & policy development, business operations, administrations, sales & marketing leadership, budgeting & cost management

MR. NITIN GUPTA

PRESIDENT - FINANCE AND GROUP CHIEF OPERATING OFFICER

Mr. Nitin Gupta is a qualified Chartered Accountant, APM from IIM Lucknow, LLB and B. Com (Hons.). He has over 21 years of work experience spearheading finance, accounting, legal & secretarial, M&A, Business Transformation, and strategic functions of large corporates. He worked as Group CFO in Asian Hospitals backed by marquee PE funds and erstwhile as Finance Controller at SRL Diagnostics (Group Company of Fortis healthcare) and with other large corporates.

MR. PANKAJ PRABHAKAR

GROUP C.F.O

Mr. Pankaj Prabhakar is a Chartered Accountant, having business experience of 23 years in accounting, cost analysis, budgeting, preparation of financial statements, internal controls, information security risk analysis. He is proficient in running successful process operations & experience of developing procedures, service standards for business of par excellence, M&A and business transformation. He has been extensively engaged in the IPO process and previously been associated with Asian Institute of Medical Sciences, Faridabad as CFO, business Analyst and Finance Head in Max Healthcare, Finance Controller in Artemis Healthcare and other leading healthcare service provider.

MR. SONU GOYAL

GROUP CHIEF FINANCIAL CONTROLLER

Mr. Sonu Goyal is a qualified Chartered Accountant and Company Secretary. He has over 16 years of work experience, out of which more than 10 years of experience is in Hospitals. He has worked as chief finance controller in Private Equity backed healthcare firm Art Fertility clinics, as regional finance controller at Fortis Hospitals, and as finance controller at Max Hospitals.

MR. RITESH MISHRA

COMPANY SECRETARY

Mr. Ritesh Mishra holds a bachelor’s degree in commerce from Awadh University, Faizabad and MBA from Sikkim Manipal University. He is an associate member of the Institute of Company Secretaries of India. He is a keen learner and adept in grasping changes in economy and its impact on health care business and stakeholders. He has rich experience the field of corporate law compliances. He extensively works with the board of the Company and instrumental in maintaining overall corporate governance at Yatharth Group of Hospitals

CORPORATE POLICIES

Sr. No. Name of Policies Download
1 Policy on Sexual Harassment of Women at Workplace
2 Nomination & Remuneration Policy
3 Code of Conduct
4 Composition of Committees of Board of Directors
5 Terms and Conditions of Appointment of Independent Directors
6 Code for Independent Directors
7 Familiarization Programme for Independent Directors 2019-20
8 Code of Conduct for Directors and Senior Management
9 Vigil Mechanism
10 Whistle blower policy
11 Related Party Transactions Policy
12 Risk Management Policy
13 Policy for Determination and Disclosure of Materiality of Events and Information
14 Criteria of making Payment to Non-Executive Directors
15 Policy on Preservation of Documents
16 Contact details of Key Managerial Personnel
17 Code of Conduct for Prevention of Insider Trading for ‘designated employees
18 Code of Practices and Procedure for Fair Disclosure of Unpublished Price
19 Policy for determining ‘material’ subsidiaries
20 Dividend Distribution Policy
21 Corporate Social Responsibility
22 Policy on diversity of board of directors
23 Archival Policy
24 Materiality Policy
25 Policy on Data Privacy and Security

CORPORATE ANNOUNCEMENTS

Sr. No. Name of Policies Download
1 Earnings Call Transcript 04.06.2025
2 Resignation Of Mr. Neeraj Vinayak 27.05.2025
3 Earning Call Recording for Q4&FY25
4 Newspaper Publication Q 4 & FY 25_27.05.25
5 Internal Auditor Reappointment_ 27.05.2025
6 Announcement under Reg 30 (LODR)-Press Release 26.05.2025
7 Board Meeting Outcome for Audited Financial Result For Q4 & FY25 26.05.2025
8 Investor Presentation for Q4 & FY 25 26.05.2025
9 Announcement under Reg. 30 (LODR)- Investor Meet- Intimation 21.05.2025
10 Intimation of Board Meeting to be held on 26.05.2025
11 Initial Disclosure -Entity identified as a Large Corporate 17.04.2025
12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Reg., 2018 11.04.2025
13 Resignation of Mr. Deepak Kumar Tyagi 31.03.2025
14 Intimation of Closure of Trading Window 29.03.2025
15 Announcement under Reg. 30 (LODR)-Updates on Acquisition 29.03.2025
16 Announcement under Reg. 30 (LODR)-Updates on Acquisition-2 29.03.2025
17 Integrated Filing (Financial) 05.03.2025
18 Information under Regulation 29(2) 10.02.2025
19 Announcement under Reg. 30 (LODR)-Press Release 10.02.2025
20 Monitoring Agency Report For Q3FY25 - QIP 06.02.2025
21 Monitoring Agency Report For Q3FY25 - IPO 06.02.2025
22 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 03.02.2025
23 Announcement under Reg. 30 (LODR)-Investor Meet - Outcome 28.01.2025
24 Board meeting intimation
25 Intimation of Board Meeting to be held on 17 August,2023
26 Analyst Investor Meet Intimation
27 Outcome of the Board Meeting
28 Intimation Press Release
29 Investor Call Recording
30 Earnings ConCall Transcript Q1 FY24
31 Intimation of Investor Meet 12.09.2023
32 Intimation of Investor Meet -1
33 Intimation of Investor Meet -2
34 Intimation Board Meeting
35 Yatharth Earning Conference Call Q2 FY24
36 Outcome of Board Meeting
37 Press Release Q2FY24
38 Yatharth Q2FY24 Earnings Presentation
39 Audio link for Yatharth Hospitals Earnings Conference
40 Newspaper Publications
41 Monitoring Agency Report
42 Transcript Yatharth Conference Call
43 Investor Meet - 28, 30 Nov 2023
44 Investor Meet - 13 Dec 2023
45 Investor Meet - 20, 21 Dec 2023
46 Investor Meet - 21 Dec 2023
47 Intimation of Closure of Trading Window
48 Certificate under Regulation 74(5) of the SEBI (DP) Reg, 2018.
49 Earning Conference Call Q3FY24
50 Investor Conference IIFL
51 Acquisition Prestine Infracon
52 Financial Result Q3 2023-24 YHTCSL
53 Yatharth Hospital_Q3FY24_Earnings Presentation
54 Yatharth Hospital_Q3FY24_Press release
55 Audio link for Yatharth Hospitals Earnings Conference Q3
56 Final Report-Q3FY24-Yatharth Hospital And Trauma Care Services Limited
57 Investor Meet
58 Investor Presentation
59 Monitoring Agency Report
60 YATHARTH 10052024204254 Exchange Announcement Pristine
61 Financial Results Yatharth Q4 FY24
62 Q4FY24 Earning Call Recording
63 Newspaper Financial Result
64 Financial Results Q1FY25
65 Yatharth Investor Presentation Q1FY25
66 Yatharth ESOP Scheme Approval
67 Yatharth Hospital Press Release Q1FY25
68 Earning_Call_Recording_Q1FY25
69 Monitoring Agency Report Q1FY25
70 Newspaper Publication Q1FY25
71 Earning Call Transcript Q1FY25
72 Exchange release Newspaper 21.08.24
73 Financial Results_Q2FY25
74 Press_Release_Q2FY25
75 Investors_Presentation_Q2FY25
76 Newspaper_Ad_Q2FY25
77 Earning_Call_Recording_Q2FY25
78 Investor Meet 251124
79 Investor_Meet_261124
80 Investor_Meet_271124
81 Investor_Meet_291124
82 Newspaper Publicaiton_Q3FY25
83 Financial Results_Q3FY25
84 Press Release_Q3_FY25
85 Investor Presentation - Q3FY25
86 Earnings Call Recording_Q3FY25

MATERIAL CREDITORS

  1. Material Creditors

QIP

DISCLAIMER

Important: You must read the following disclaimer before continuing.

Please read this notice carefully. It applies to all persons who view this website. Viewing this information may not be lawful in certain jurisdictions. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the website. By accessing this information on this website, you agree to the terms and conditions below, including any modifications that may be made to them from time to time.

These materials are not directed at or intended to be accessed by persons located in the United States or other jurisdictions outside India and are intended for distribution to, and use by, residents of India only.

These materials are being made available on this website by Yatharth Hospital & Trauma Care Services Limited ("Company") solely to comply with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and the Companies Act, 2013 and the rules made thereunder, each as amended ("Companies Act"). Making the preliminary placement document dated December 18, 2024 available in electronic format on this website does not constitute an offer to sell or the solicitation of an offer to buy equity shares in the proposed qualified institutions placement ("Issue") in any jurisdiction.

Nothing herein constitutes an offer of securities for sale in any jurisdiction where it is unlawful to do so. You are reminded that you have accessed the preliminary placement document on the basis that you are a person into whose possession the documents may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located.

This disclaimer applies to all persons who view this website. The following disclaimer applies to the preliminary placement document in relation to the proposed qualified institutions placement of equity shares ("Equity Shares") of the company filed with BSE Limited and the National Stock Exchange of India Limited ("Stock Exchanges") ("Preliminary Placement Document"). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the preliminary placement document.

The equity shares offered in the issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state securities laws in the United States, and unless so registered, and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any applicable U.S. state securities laws. You understand that the equity shares offered in the issue are being offered and sold only outside the United States in "offshore transactions", as defined in and in reliance on Regulation S under the U.S. Securities Act ("Regulation S") and you represent that you were outside the United States when the offer to purchase the equity shares was made to you and you are currently outside the United States and that you are not acquiring or subscribing for the equity shares as a result of any "directed selling efforts" (as defined in Regulation S).

The preliminary placement document presented herein is placed solely to comply with the provisions of Chapter VI of the SEBI ICDR Regulations and Sections 42 and 62 of the Companies Act. Access to this website shall not form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. We are not soliciting any action or decision based on the information on this website.

The preliminary placement document has not been and will not be filed as a prospectus or a statement in lieu of prospectus with any registrar of companies in India under the Companies Act. The preliminary placement document shall be filed as a private placement offer letter with the stock exchanges. The preliminary placement document is exclusive to the recipient and is not intended and does not constitute an offer or a solicitation or invitation of an offer to subscribe to the securities described in the preliminary placement document to the general public or any person or class of investors other than eligible qualified institutional buyers, as defined in the SEBI ICDR Regulations. The preliminary placement document has not been reviewed and approved by any regulatory authority in India or abroad, including the Securities and Exchange Board of India, Reserve Bank of India, any registrar of companies in India or any stock exchange in India. The preliminary placement document is not and should not be construed as an invitation, offer or sale of any securities to the public in India.

None of the company, the lead managers and any of their respective affiliates, accepts any liability whatsoever, direct or indirect, that may arise from the use of the information contained on this website. Access to this website or the preliminary placement document does not constitute a recommendation by the company, the lead managers, any of their respective affiliates or any other party to subscribe to or buy or sell the equity shares. Making press announcements and other documents available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy equity shares in the company. The preliminary placement document, will not be circulated or distributed to the public in India or any other jurisdiction, and will not constitute a public offer in India or any other jurisdiction.

The information in the preliminary placement document is as of the date thereof and neither the company, its directors nor the lead managers are under any obligation to update or revise the preliminary placement document to reflect circumstances arising after the date thereof.

The issue, and the distribution of the preliminary placement document is being made to qualified institutional buyers as defined under the SEBI ICDR Regulations ("QIBs") which are not restricted from participating in the issue under the applicable laws, including the SEBI ICDR Regulations, are eligible to invest in this issue ("Eligible QIBs") in reliance upon Chapter VI of the SEBI ICDR Regulations and Sections 42 and 62, and other applicable provisions of the Companies Act. Unless a serially numbered preliminary placement document accompanied by an application form is addressed to a specific QIB inviting such QIB to make a bid through such application form, no offer and/or invitation of offer shall be deemed to have been made. You acknowledge that access to the preliminary placement document is intended for use by you only and you agree not to forward the preliminary placement document on to any other person, in whole or in part, or otherwise provide access via e-mail or otherwise to any other person.

You are accessing this website at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. Neither the company, the lead managers nor any of their affiliates, directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials. It is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature.

The preliminary placement document may contain statements about future events and expectations that constitute forward-looking statements. There can be no assurance that the results and events contemplated by the forward-looking statements contained there will in fact occur. The company, its directors, the lead managers or any of their respective affiliates do not make any representation or warranty, express or implied, as to, and do not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinion in the preliminary placement document.

If you access the preliminary placement document contrary to the foregoing restrictions, you will be ineligible to purchase the securities.

Investing in the equity shares described in the preliminary placement document presented herein involves risks and you should not invest any funds in the equity shares unless you are prepared to risk losing all or part of your investment. You are advised to carefully read the risk factors and the other information contained in the preliminary placement document presented herein before making an investment decision. You are advised to consult your own advisors about the particular consequences of investing in the equity shares described in the preliminary placement document.

The preliminary placement document may not be downloaded, delivered, forwarded or distributed, electronically or otherwise, in whole or in part, to any other person and may not be reproduced in any manner whatsoever. Any downloading, forwarding, delivery, distribution or reproduction of the preliminary placement document in whole or in part is unauthorized. Failure to comply with this disclaimer may result in a violation of the applicable laws.

You are accessing the materials on this website on the basis that you are a person into whose possession these material may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located. If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

I certify that I am authorized to access this site.

Confirmation

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access, you:

  • Are located and resident in India
  • Are not a resident of the United States and you are not located inside the United States
  • Are eligible to invest

Select Country

Please indicate which country you are accessing the document from:

MEMORANDUM AND ARTICLES OF ASSOCIATION

GRIEVANCE & REDRESSAL

REGISTRAR & SHARE TRANSFER AGENT

  • MUFG Intime India Private Limited
    (Formerly Known as Link Intime India Pvt. Ltd.)
    C-101, 1st Floor, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
    Tel: +91 22 810 811 4949
    E-mail: yatharth.ipo@linkintime.co.in
    Investor Grievance E-mail: yatharth.ipo@linkintime.co.in
    Contact Person: Shanti Gopalkrishnan
    URL of SEBI Website: Click here
    SEBI Reg. No.: INR000004058
    CIN: U67190MH1999PTC118368


       

    Mr Ritesh Mishra

    Company Secretary & Compliance Officer
    E-mail : cs@yatharthhospitals.com
    Tel : +911206811236
    Address : HO-01, Sector-1, Noida Extension, Gautam Buddha Nagar, Uttar Pradesh-201306